Showing results (731-740 of 745) with videos related to

Sort By:
Pageof 75
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
Discovery of novel BTK inhibitors with carboxylic acidsXiaolei Gao, James Wang, Jian Liu, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Bioorganic & Medicinal Chemistry Letters|May 12, 2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncologySobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutesJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
COVID-19 and metabolic disease: mechanisms and clinical managementCharlotte Steenblock, Peter E H Schwarz, Barbara Ludwig, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for OncologySobhana Babu Boga, Yongqi Deng, Liang Zhu, et al.
Medical Image Analysis|August 1, 2016
ISLES 2015 - A public evaluation benchmark for ischemic stroke lesion segmentation from multispectral MRIOskar Maier, Bjoern H Menze, Janina von der Gablentz, et al.
Pageof 75